NeuroPace, Inc. (NASDAQ:NPCE) Given Average Rating of “Moderate Buy” by Analysts

Shares of NeuroPace, Inc. (NASDAQ:NPCE) have received an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $14.50.

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company decreased their price target on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th. JPMorgan Chase & Co. increased their target price on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday.

NeuroPace Price Performance

NPCE opened at $11.14 on Friday. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. The stock has a market capitalization of $332.51 million, a PE ratio of -11.14 and a beta of 2.05. The stock’s 50 day moving average price is $8.71 and its 200-day moving average price is $7.67. NeuroPace has a 52-week low of $5.45 and a 52-week high of $18.15.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The business had revenue of $21.06 million for the quarter, compared to the consensus estimate of $19.33 million. During the same period in the previous year, the firm earned ($0.28) EPS. On average, equities research analysts predict that NeuroPace will post -1 EPS for the current year.

Insider Activity

In other news, major shareholder Ltd. Kck sold 4,910 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $6.66, for a total transaction of $32,700.60. Following the completion of the transaction, the insider now directly owns 5,540,104 shares in the company, valued at $36,897,092.64. This trade represents a 0.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders sold 257,590 shares of company stock worth $1,437,916. Insiders own 22.20% of the company’s stock.

Hedge Funds Weigh In On NeuroPace

Several hedge funds and other institutional investors have recently modified their holdings of NPCE. Millennium Management LLC grew its holdings in shares of NeuroPace by 13.3% in the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after acquiring an additional 80,324 shares during the period. Acadian Asset Management LLC boosted its position in NeuroPace by 46.0% in the second quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock worth $520,000 after purchasing an additional 21,703 shares during the last quarter. Financial Advocates Investment Management grew its stake in shares of NeuroPace by 50.0% during the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after purchasing an additional 5,000 shares during the period. Rhumbline Advisers purchased a new stake in shares of NeuroPace during the 2nd quarter valued at about $111,000. Finally, XTX Topco Ltd lifted its stake in shares of NeuroPace by 56.1% in the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after purchasing an additional 8,643 shares during the period. 78.83% of the stock is owned by institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.